Skip to main content

Table 2 Effect of different types of stem cells on renal tissue oxidative stress parameters (n = 20 and n = 5 for day subgroups, mean ± SD)

From: Comparative study of allogenic and xenogeneic mesenchymal stem cells on cisplatin-induced acute kidney injury in Sprague-Dawley rats

  Group I Group II Group III Group IV Group V Group VI
negative control cisplatin ‘CDDP’-treated cisplatin + rBMSCs-treated cisplatin + hADSCs-treated cisplatin + hAFSCs-treated cisplatin + DMEM culture media-treated
MDA (nmol/gm tissue)
 Day 4 14.6 ± 1.61 66.5 ± 2.83a 34.7 ± 4.95ab 37.0 ± 3.75ab 34.7 ± 6.72ab 66.6 ± 2.86acde
 Day 7 14.9 ± 1.50 64.9 ± 3.93a 24.5 ± 4.98ab 28.0 ± 2.58ab 26.1 ± 2.13ab 66.9 ± 2.29acde
 Day 11 15.4 ± 1.63 35.5 ± 3.33a 18.4 ± 0.93b 18.3 ± 2.20b 17.8 ± 1.78b 34.8 ± 2.84acde
 Day 30 15.1 ± 1.62 30.1 ± 4.61a 16.2 ± 0.87b 18.7 ± 2.32b 17.6 ± 2.29b 28.1 ± 1.58acde
GSH (mmol/gm tissue)
 Day 4 5.40 ± 0.25 0.26 ± 0.03a 0.78 ± 0.04ab 0.81 ± 0.11ab 0.76 ± 0.02ab 0.26 ± 0.02acde
 Day 7 5.44 ± 0.23 0.54 ± 0.03a 2.65 ± 0.15ab 2.72 ± 0.17ab 2.64 ± 0.36ab 0.52 ± 0.03acde
 Day 11 5.55 ± 0.17 1.49 ± 0.33a 3.36 ± 0.14ab 3.68 ± 0.13ab 3.55 ± 0.15ab 1.32 ± 0.30acde
 Day 30 5.32 ± 0.31 1.92 ± 0.03a 5.05 ± 0.12b 4.29 ± 0.18abc 3.98 ± 0.43abc 1.91 ± 0.05acde
SOD (U/g of tissue)
 Day 4 20.36 ± 1.70 2.98 ± 0.19a 7.64 ± 0.37ab 6.87 ± 0.39ab 6.93 ± 0.42ab 2.94 ± 0.23acde
 Day 7 19.92 ± 1.39 6.24 ± 0.42a 10.85 ± 0.38ab 10.31 ± 0.36ab 10.69 ± 0.33ab 6.22 ± 0.45acde
 Day 11 19.88 ± 1.40 9.98 ± 0.32a 15.46 ± 0.32ab 15.80 ± 0.25ab 15.73 ± 0.29ab 10.0 ± 0.25acde
 Day 30 20.22 ± 1.70 15.3 ± 0.36a 18.26 ± 0.17ab 18.62 ± 0.38ab 18.74 ± 0.15b 15.6 ± 0.49acde
  1. Values are expressed as mean ± SD. A significant difference (P < 0.05) between different groups was done by Bonferroni post hoc for multiple comparisons
  2. rBMSCs rat bone marrow stem cells, hADSCs human adipose tissue-derived stem cells, hAFSCs human amniotic fluid-derived stem cells, DMEM Dulbecco’s modified Eagle’s medium, MDA malondialdehyde, GSH reduced glutathione, SOD superoxide dismutase
  3. aSignificant difference vs. negative control group bSignificant difference vs. cisplatin-treated group cSignificant difference vs. cisplatin + rBMSCs-treated group dSignificant difference vs. cisplatin + hADSCs-treated group eSignificant difference vs. cisplatin + hAFSCs-treated group